touchHAEMATOLOGY touchHAEMATOLOGY
Hodgkin Lymphoma
Watch Time: 2 mins

Stephen Ansell: Hodgkin lymphoma – what are the treatment challenges?

Copy Link
Published Online: Feb 20th 2023
Authors: Stephen Ansell

Dr Stephen Ansell (Mayo Clinic, Rochester, MN, USA) discusses the challenges and unmet needs in the front-line treatment of Hodgkin lymphoma. Firstly, as a curable disease in around 75% of patients one challenge is finding a cure in more patients. Secondly, in the patients who are cured, can we minimise long-term complications such as fatigue, fertility or pregnancy issues and bone marrow damage.

Disclosures: Stephen Ansell has received grant/research support from ADC Therapeutics, Affimed, BMS, Pfizer, Regeneron, SeaGen and Takeda and is on the advisory board for Affimed.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson originally for touchONCOLOGY.com.

Transcript:

What are the challenges and unmet needs in the frontline treatment of Hodgkin lymphoma?

I’m Steve, and so I’m a professor of Medicine at Mayo clinic, and I’m chair of the hematology department. Well, Hodgkin lymphoma, as some people may know, is a cancer of lymphocytes. And in patients with this disease, they often are young patients, although they can still be a second peak in the elderly. And the reason that this can be a challenging disease is because clearly we would like to get the disease under control and have the patient go back to a normal, healthy life and get entirely back to normal, because this is a disease that we can potentially cure with current therapy. So that really brings the challenges. The challenge, number one, is, can we cure more people? In general, I think the thinking is probably around 75% of patients can be cured, but 25% of patients is the challenge to cure everybody. And the second challenges in the patients in whom we are able to cure the disease, have we created long term complications that remain a challenge for patients in the future? And those complications can be damage to the bone marrow, severe fatigue, pregnancy problems in the future. So we’re always looking for maximum benefit with fewer side effects.

Interested in more content on the topic of lymphoma? Here are some of our recent videos and articles:

Prof. Swaminathan Iyer discusses the TRIANGLE phase III study and the role of transplant and biologics in mantle cell lymphoma

Dr William Townsend shares the final analysis of the GALLIUM study of obinutuzumab plus chemotherapy in patients with follicular lymphoma

Related Videos In Hodgkin Lymphoma
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72